SCHEMBL13899210

SCHEMBL13899210

COC(=O)C(=O)c1c[nH]c2c(C)ncc(OC)c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.44
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C8 P10632 1/20 0.41
CYP2B6 P20813 1/20 0.41
CYP2C19 P33261 1/20 0.41
KCNH2 Q12809 1/20 0.41
KDM4E B2RXH2 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
NR4A2 P43354 1/20 0.33
CNR2 P34972 2/20 0.33
JAK3 P52333 3/20 0.33
JAK2 O60674 1/20 0.33
CNR1 P21554 1/20 0.32
AAK1 Q2M2I8 1/20 0.32
SYK P43405 1/20 0.32
HTR2C P28335 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12238398 0.88 CYP2C9 (0.47) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL13119403 0.86 CYP2C9 (0.57) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL1762967 0.85 CYP2C9 (0.43) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL3933553 0.85 CYP2C9 (0.43) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL1473243 0.81 CYP2C9 (0.39) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL4070811 0.79 CYP2C9 (0.42) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL2629197 0.79 CYP3A4 (0.65) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL2629228 0.79 CYP3A4 (0.47) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL10292446 0.79 CYP3A4 (0.47) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL1472512 0.79 CYP2C9 (0.38) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501419-B2 4-Squarylpiperazine derivatives as antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2009-03-10 US disclosed
US-20070249624-A1 4-Squarylpiperazine Derivatives as Antiviral Agents BRISTOL-MYERS SQUIBB COMPANY 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249624-A1 4-Squarylpiperazine Derivatives as Antiviral Agents MAVS, MTAP, SAMHD1 CYP2C9 1983/4885CYP3A4 110/4885CYP2D6 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.